AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 8.2 |
Market Cap | 1.26B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 0.57 |
PE Ratio (ttm) | 15.08 |
Forward PE | n/a |
Analyst | Buy |
Ask | 8.5 |
Volume | 583,323 |
Avg. Volume (20D) | 827,147 |
Open | 8.60 |
Previous Close | 8.56 |
Day's Range | 8.54 - 8.66 |
52-Week Range | 5.47 - 10.14 |
Beta | undefined |
About MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its produc...
Analyst Forecast
According to 5 analyst ratings, the average rating for MDXG stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 33.80% from the latest price.
Next Earnings Release
Analysts project revenue of $87.64M, reflecting a 0.93% YoY growth and earnings per share of 0.06, making a 50.00% increase YoY.